Rhythm Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing therapies for rare diseases. Their lead asset, IMCIVREE (setmelanotide), targets hyperphagia and severe obesity caused by rare MC4R pathway diseases. With revenue generated primarily from the US, the company is dedicated to advancing precision medicine for patients in need. Analysts’ assessments provide valuable insights into […]